menu search

Aclaris therapeutics to participate in the h.c. wainwright global investment conference

WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developi...

May 16, 2022, 7:00 am

X4 pharmaceuticals to present research data at the 2022 european hematology association (eha) congress supporting mechanism and market potential for mavorixafor

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of ...

May 16, 2022, 6:05 am

Obseva to host conference call and webcast to discuss first quarter 2022 financial results and provide business update

GENEVA, Switzerland – May 1 2 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing ...

May 12, 2022, 1:00 am

Acumen pharmaceuticals to report first quarter 2022 financial results on may 16, 2022

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutica...

May 11, 2022, 5:08 pm

Pfizer deal will help expand reach of migraine pill nurtec, biohaven ceo says

"We have to bring the modern day, novel therapies to those patients, and Pfizer really is the best comp...

May 10, 2022, 7:11 pm

Karyopharm to participate at the 2022 rbc capital markets global healthcare conference

NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering ...

May 10, 2022, 7:00 am

Finch therapeutics to host corporate update conference call and webcast on may 16, 2022

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinica...

May 9, 2022, 8:22 am

Novocure: a stalwart with more upsides

Though there are many companies to choose from, I focus on leading innovators with either novel therape...

May 9, 2022, 6:38 am

Teknova to report first quarter 2022 financial results on may 11, 2022

HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for th...

May 4, 2022, 5:18 pm

X4 pharmaceuticals to announce first quarter 2022 financial results and host a conference call and webcast on may 12, 2022

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of ...

May 3, 2022, 6:05 am

Athenex, texas children's cancer center, and the center for cell and gene therapy at baylor college of medicine to present phase 1 clinical data for kur-501, an autologous gd2 car-nkt cell therapy for

BUFFALO, N.Y., May 02, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, an...

May 2, 2022, 5:27 pm

Athenex, texas children's cancer center, and the center for cell and gene therapy at baylor college of medicine to present phase 1 clinical data for kur-501, an autologous gd2 car-nkt cell therapy for

BUFFALO, N.Y., May 02, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, an...

May 2, 2022, 5:27 pm

Ocugen to host conference call on friday, may 6 at 8:30 a.m. et to provide business update and discuss first quarter 2022 financial results

MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commerciali...

May 2, 2022, 7:37 am

Astrazeneca's tremelimumab/imfinzi combo regime goes under priority fda review for liver cancer

The FDA has accepted for review AstraZeneca Plc's (NASDAQ: AZN) marketing application for tremelimumab as a single priming dose added to Imfinzi (d...

April 25, 2022, 7:15 am

Astrazeneca says tremelimumab accepted for us priority review for imfinzi combo for liver cancer treatment

AstraZeneca PLC (LSE:AZN) said its Biologics License Application (BLA) for tremelimumab, an anti-CTLA4 antibody, has been accepted for Priority Revie...

April 25, 2022, 2:39 am

Ocugen, inc. to present at noblecon18

MALVERN, Pa., April 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commerci...

April 19, 2022, 5:32 pm

Hoth therapeutics adds new pipeline program for stroke, brain injury

Hoth Therapeutics Inc (NASDAQ: HOTH) has added a new asset, HT-TBI, as a novel, point-of-care therapy to treat secondary brain injury resulting from...

April 19, 2022, 3:37 pm

Tesla recalls nearly 600,000 evs over boombox feature, again

This is the second large recall for the controversial novelty feature. Don't worry, Tesla owners, an OTA patch should solve it....

April 15, 2022, 11:16 am

Hostess brings a novel distribution approach to a mature industry

Hostess is an old brand growing in a new company. Hostess uses a Direct-to-Warehouse strategy that cuts costs and adds market share gain opportunities...

April 13, 2022, 4:28 am

Matinas (mtnb) up on deal with biontech for mrna vaccines

Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel ...

April 12, 2022, 4:33 pm


Search within

Pages Search Results: